While retroviral vectors (RVVs) are driving a new wave of innovation in cell and gene therapy (CGT), biotechs still face significant technical hurdles on the path to commercialization.
These challenges range from low yields and material loss during sterile filtration to the limited scalability of traditional adherent manufacturing methods and the inherent fragility of the vectors themselves.
Our latest eBook looks at how to navigate these complexities. In it, you’ll learn:
- Why RVVs are regaining ground in the CGT space
- Upstream techniques for achieving higher cell densities using fixed-bed bioreactors
- Practical downstream strategies for handling fragile, enveloped RV particles
- How to ensure regulatory readiness with phase-appropriate analytical methods
- The value of a flexible partnership model combining deep RVV specialization and integrated manufacturing.
